Clemow David, Radawski Christine, Milata Joe, Alaka Karla, Gibble Theresa Hunter, Schaum Adam, Ezennia Obi, Martinez Nicholas, Szaloki Tibor, Ito Yuka, Rodriguez Danielle, Kirk Katherine
Eli Lilly and Company, Indianapolis, IN, USA.
Gastroenterology Research of America, San Antonio, TX, USA.
Crohns Colitis 360. 2024 Oct 4;6(4):otae054. doi: 10.1093/crocol/otae054. eCollection 2024 Oct.
There is a need to better understand ulcerative colitis (UC) patient and healthcare provider (HCP) treatment satisfaction, acceptability, and preferences.
Two international, cross-sectional, web-based surveys were conducted among participants of a phase 3 mirikizumab study (NCT03519945). The questions captured moderate-to-severe UC patients' experience, HCPs' perception of patients' experience, and HCPs' own experience with mirikizumab administration through intravenous (IV) infusions and subcutaneous (SC) injections.
Respondents included 93 patients and 42 HCPs from 11 countries. The majority of patients had UC >4 years (74.2%), were bionaive (68%), in remission at the time of the survey (63%). HCPs were primarily from the United States (57%), generally nurses (41%) or gastroenterologists (26%) with ≥6 years of experience in treating UC (57%). Most patients were "very satisfied/satisfied" (IV, 83%; SC, 91%), "completely/somewhat" accepting of mirikizumab administration (IV, 87%; SC, 97%), and agreed that improvement to their UC outweighed any administration dissatisfaction (90%). HCPs' perspectives of patients' experiences were higher: "very satisfied/satisfied" (IV, 93%; SC, 100%); "completely/somewhat" accepting (IV, 90%; SC, 98%). HCPs themselves were "very satisfied/satisfied" (IV, 81%; SC, 95%); gastroenterologists were "very satisfied" (IV, 82%; SC, 82%) more than nurses (IV, 29%; SC, 65%) who were generally at least "satisfied" (IV, 53%; SC, 35%). Two SC and monthly SC injections were "completely acceptable" by the patients (76% and 85%) and per HCPs' perceptions of patients' preferences (69% and 100%).
Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction.
有必要更好地了解溃疡性结肠炎（UC）患者及医疗服务提供者（HCP）对治疗的满意度、可接受性和偏好。
在一项3期mirikizumab研究（NCT03519945）的参与者中开展了两项基于网络的国际横断面调查。问题涵盖了中重度UC患者的体验、HCP对患者体验的看法以及HCP自身通过静脉（IV）输注和皮下（SC）注射使用mirikizumab的经历。
受访者包括来自11个国家的93名患者和42名HCP。大多数患者患UC超过4年（74.2%），未使用过生物制剂（68%），在调查时处于缓解期（63%）。HCP主要来自美国（57%），通常是护士（41%）或胃肠病学家（26%），治疗UC的经验≥6年（57%）。大多数患者“非常满意/满意”（IV组为83%；SC组为91%），“完全/ somewhat”接受mirikizumab给药（IV组为87%；SC组为97%），并认为UC的改善超过了对给药的任何不满（90%）。HCP对患者体验的看法更高：“非常满意/满意”（IV组为93%；SC组为100%）；“完全/ somewhat”接受（IV组为90%；SC组为98%）。HCP自身“非常满意/满意”（IV组为81%；SC组为95%）；胃肠病学家“非常满意”（IV组为82%；SC组为82%）的比例高于护士（IV组为29%；SC组为65%），护士一般至少“满意”（IV组为53%；SC组为35%）。两次SC注射和每月一次SC注射被患者“完全接受”（分别为76%和85%），且符合HCP对患者偏好的看法（分别为69%和100%）。
患者和HCP都对mirikizumab静脉诱导继以每月一次皮下维持注射感到满意并接受。UC的改善超过了对给药的任何不满。
